Basis of Presentation (Tables)

9 Months Ended

Nov. 30, 2019

Basis of Presentation

Schedule of impact of the Company's adoption of the ASU on the prior period consolidated balance sheet

	Impact of change in accounting policy
(in thousands)	As reported				As adjusted
	March 2, 2019		Adjustments		March 3, 2019
ASSETS
Current assets:
Cash and cash equivalents	$	144,353	$	—	$	144,353
Accounts receivable, net		1,788,712		—		1,788,712
Inventories, net		1,871,941		—		1,871,941
Prepaid expenses and other current assets		179,132		(51,448)		127,684
Current assets held for sale		117,581		43,697		161,278
Total current assets		4,101,719		(7,751)		4,093,968
Property, plant and equipment, net		1,308,514		—		1,308,514
Operating lease right-of-use asset		—		3,026,976		3,026,976
Goodwill		1,108,136		—		1,108,136
Other intangibles, net		448,706		(29,632)		419,074
Deferred tax assets		409,084		—		409,084
Other assets		215,208		(1,086)		214,122
Total assets	$	7,591,367	$	2,988,507	$	10,579,874
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	16,111	$	—	$	16,111
Accounts payable		1,618,585		—		1,618,585
Accrued salaries, wages and other current liabilities		808,439		(56,553)		751,886
Current portion of operating lease liabilities		—		457,305		457,305
Current liabilities held for sale		—		45,167		45,167
Total current liabilities		2,443,135		445,919		2,889,054
Long-term debt, less current maturities		3,454,585		—		3,454,585
Long-term operating lease liabilities		—		2,838,022		2,838,022
Lease financing obligations, less current maturities		24,064		—		24,064
Other noncurrent liabilities		482,893		(238,658)		244,235
Total liabilities		6,404,677		3,045,283		9,449,960
Commitments and contingencies		—		—		—
Stockholders’ equity:
Common stock, par value $1 per share; 75,000 shares authorized; shares issued and outstanding 54,016		54,016		—		54,016
Additional paid-in capital		5,876,977		—		5,876,977
Accumulated deficit		(4,713,244)		(56,776)		(4,770,020)
Accumulated other comprehensive loss		(31,059)		—		(31,059)
Total stockholders’ equity		1,186,690		(56,776)		1,129,914
Total liabilities and stockholders’ equity	$	7,591,367	$	2,988,507	$	10,579,874

Schedule of revenues

	Thirteen Week Period Ended		Thirty-Nine Week Period Ended
In thousands	November 30, 2019		November 30, 2019
Retail Pharmacy segment:
Pharmacy sales	$	2,623,832	$	7,761,052
Front-end sales		1,250,946		3,767,796
Other revenue		35,168		94,010
Total Retail Pharmacy segment		3,909,946		11,622,858
Pharmacy Services segment		1,613,109		4,758,470
Intersegment elimination		(60,757)		(180,177)
Total revenue	$	5,462,298	$	16,201,151